EDQM 修订 PA/PH/CEP (14) 06 指南以配合 CEP 2.0 实施
CEP 2.0: EDQM Updates Guidance on the Use of Certificates of Suitability
EDQM 修订了 PA/PH/CEP (14) 06 指南,说明如何用既有 CEP 描述另一份 CEP 申请中的物料。修订配合 CEP 2.0 实施,并与 EMA 问答文件 EMA/CHMP/CVMP/QWP/5/2024 中关于 CEP 用于上市许可申请或变更的原则保持一致。
The European Directorate for the Quality of Medicines & HealthCare (EDQM) has revised guidance document PA/PH/CEP (14) 06. The document explains how a Certificate of Suitability to the monographs of the European Pharmacopoeia (CEP) may be used to describe a material included in an application for another CEP.The revision reflects the implementation of CEP 2.0 and brings the guidance into line with the principles outlined in the EMA Questions and Answers document on the use of a CEP in a Marketing Authorisation Application or a Marketing Authorisation Variation (EMA/CHMP/CVMP/QWP/5/2024). Key points of the revisionThe updated guidance provides current regulatory direction for CEP applicants and holders, particularly with regard to: the requirements and structure of CEP 2.0; the relationship between the EDQM guidance and the relevant EMA principles; the use of an existing CEP to describe a material in a further CEP application.Background to the original documentThe original version of PA/PH/CEP (14) 06 was developed to clarify how a CEP could be used to support the description of a material in another CEP application. It provided practical guidance for applicants and CEP holders using an existing certificate in the context of a further CEP procedure. Following the introduction of CEP 2.0 and the development of related EMA guidance, an update of the document became necessary.Practical implicationsCEP applicants and holders should consult the revised guidance when preparing new applications or updating existing CEP documentation. In particular, companies should review the relevant parts of their dossiers where a CEP is used to describe a starting material, intermediate or other material included in another CEP application.
来源:ECA GMP News · gmp-compliance.org